Overview

This trial is active, not recruiting.

Condition chronic lymphocytic leukemia
Treatment cpg 7909
Phase phase 1
Sponsor University of Iowa
Collaborator Mayo Clinic
Start date July 2004
Trial size 48 participants
Trial identifier NCT00233506, 200402002

Summary

- CpG has the potential to stimulate the immune system

- this study will evaluate the safety of CpG given sub-q or IV

- purpose is to measure biological changes in CLL cells after receiving CpG

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification bio-availability study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Diagnosis of CLL - CLL previously treated - Hemoglobin >/= 10 - Platelets >/= 50,000 - Neutrophils >= 1,000 - Exclusion Criteria: - patients with brain mets - patients with autoimmune disease - patients on corticosteroids or immunosuppressants - patients with uncontrolled intercurrent illness - pregnant women - HIV patients receiving combination anti-retroviral therapy

Additional Information

Official title A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia
Principal investigator Brian Link, MD
Trial information was received from ClinicalTrials.gov and was last updated in June 2010.
Information provided to ClinicalTrials.gov by University of Iowa.